Stockreport

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

Precision BioSciences, Inc.  (DTIL) 
Last precision biosciences, inc. earnings: 11/12 07:15 am Check Earnings Report
PDF - Treatment with ECUR-506 resulted in a complete clinical response from three months post exposure to the end of study (six months post exposure)- ECUR-506 was generally [Read more]